The issue of universal and free access to treatment is now a fundamental goal of the international community. Based on original data and field studies from Brazil, Thailand, India and Sub-Saharan Africa under the aegis of ANRS (the French nationalagency for research on Aids and viral hepatitis, this timely and significant book both assesses the progress made in achieving this objective and presents a rigorous diagnosis of the obstacles that remain. Placing particular emphasis on the constraints imposed by TRIPS as well as the poor state of most public health systems in Southern countries, the contributing authors provide a comprehensive analysis of the huge barriers that have yet to be overcome in order to attain free access to care and offer innovative suggestions of how they might be confronted. In doing this, the book renews our understanding of the political economy of HIV/AIDS in these vast regions, where the disease continues to spread with devastating social and economic consequences. This volume will be a valuable addition to the current literature on HIV/AIDS in developing countries and will find widespread appeal amongst students and academics studying economics, sociology and public health. It will also be of interest to international organizations and professional associations involved in the fight against pandemics.

Reports on the U.S. Agency for International Development (AID) and its lack of an agencywide strategy for marshaling resources to combat the AIDS epidemic in developing countries through the foreign assistance it makes available.

Globally, action to prevent HIV spread is inadequate. Over 16,000 new infections occur every day. Yet we are not helpless in the face of disaster, as shown by the rich prevention experience analyzed in this valuable new compendium. “Best pr- tice” exists—a set of tried and tested ways of slowing the spread of HIV, of persuading and enabling people to protect themselves and others from the virus. Individually, features of best practice can be found almost everywhere. The tragedy, on a world scale, is that prevention is spotty, not comprehensive; the measures are not being applied on anywhere near the scale needed, or with the right focus or synergy. The national response may concentrate solely on sex workers, for example. Elsewhere, efforts may go into school education for the young, but ignore the risks and vulnerability of men who have sex with men. Action may be patchy geographically. AIDS prevention may not benefit from adequate commitment from all parts and sectors of society, compromising the sustainability of the response. In some countries matters are still worse—there is still hardly any action at all against AIDS and scarcely any effort to make HIV visible. It is no wonder that the epidemic is still emerging and in some places is altogether out of control.

Based on careful analysis of burden of disease and the costs ofinterventions, this second edition of 'Disease Control Priorities in Developing Countries, 2nd edition' highlights achievable priorities; measures progresstoward providing efficient, equitable care; promotes cost-effectiveinterventions to targeted populations; and encourages integrated effortsto optimize health. Nearly 500 experts - scientists, epidemiologists, health economists,academicians, and public health practitioners - from around the worldcontributed to the data sources and methodologies, and identifiedchallenges and priorities, resulting in this integrated, comprehensivereference volume on the state of health in developing countries.

Hearing on the spread of the HIV/AIDS virus, which has become the No. 1 killer of people aged 16-45 in most of the world's nations. Witnesses: Anthony Fauci, Nat. Inst. of Allergy & Infectious Diseases; Deborah Birx, U.S. Mil. HIV Research Prog.; Paul De Lay, Chief of HIV/AIDS Div., U.S. Agency for Internat. Develop.; Peter Piot, Exec. Dir., UNAIDS; Nils Daulaire, Pres., Nat. Council for Internat. Health/Global Health Council; Peter Young, HIV & Opportunistic Infections Therapeutic Develop. & Product Strategy, Glaxo Wellcome R&D; & Michael Merson, Dean of Public Health & Prof., Dept. of Epidemiology & Public Health, Yale Univ. School of Med.

These crochet jackets from Coats & Clark let you change your wardrobe whenever you change your mood. Is it a day for quick decisions and getting things done? Toss on Confident, a button-down coat with a hem that cruises below the hip. If being Serene is more your thing, then mix a playful puff stitch with shades of green to create a jacket as peaceful as a forest retreat. Hunting for a way to buck the trends? The Bold jacket is camo-inspired, but it won t let you get lost in a crowd. Romantic is a cropped hoodie that hugs your shoulders and frames your face with soft bobbles. 4 jackets to crochet: Confident by Angel Rhett (sizes 8, 10, 12) ; Serene and Romantic, both by Ann E. Smith (sizes S, M, L, XL) ; and Bold by Kathleen Sams (sizes S, M, L) .

Forty years ago, the age-old battle against infectious diseases as a major threat to human health was believed close to being won. However, by the late twentieth century, the increase of emerging and reemerging infectious diseases was evident in both low and high income countries. About 30 new infectious diseases have been identified in the last 20 years. Among the "new" diseases, and most importantly, the Human Immunodeficiency Virus (HIV) epidemic, with 40 million persons infected and 25 million deaths since its first description, presents one of the most significant health, societal and security challenges facing the global community. The interaction of HIV/AIDS with tuberculosis, malaria and bacterial infections have increased HIV-related morbidity and mortality, and in turn, the HIV pandemic has brought about devastating increases in tuberculosis. Understanding the population impact and the dynamics of infection diseases in the most affected region is critical to efforts to reduce the morbidity and mortality of such infections, and for decisions on where to use limited resources in the fight against infections. This book aims to contribute to these efforts by offering a demographic and epidemiological perspective on emerging and reemerging infections in sub-Saharan Africa.